跳至主要内容
临床试验/NCT00104845
NCT00104845已完成1 期

Injection of AJCC Stage IIB, IIC, III, and IV Melanoma Patients With Human and Mouse gp100 DNA: A Phase I Trial to Assess Safety and Immune Response

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2004年9月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
19
试验地点
1
主要终点
safety and feasibility

研究概览

简要总结

RATIONALE: Vaccines made from DNA may make the body build an effective immune response to kill tumor cells.

PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma.

详细描述

OBJECTIVES:

Primary

  • Determine the safety and feasibility of vaccination with human and mouse gp100 DNA in patients with stage IIB, IIC, III, or IV melanoma.
  • Determine the maximum tolerated dose of this regimen in these patients.
  • Compare the antibody and T-cell response in patients treated with two different vaccination schedules.

Secondary

  • Assess antitumor response in patients treated with this regimen.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

safety and feasibility

时间窗: 2 years

次要结局

  • maximum tolerated dose(2 years)
  • antibody and T-cell response(2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验